Vivus (VVUS) Surges as Qsymia Prescriptions Rise 46%
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Price: $0.47 --0%
Rating Summary:
3 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
3 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Vivus, Inc. (NASDAQ: VVUS) is stronger early Monday following positive script data.
Analysts at Bloomberg Industries noted that Qsymia prescriptions gained 46% week-over-week, citing data from Symphony Health Solutions.
Shares of Vivus last traded at $12.55, up 9.3 percent.
Analysts at Bloomberg Industries noted that Qsymia prescriptions gained 46% week-over-week, citing data from Symphony Health Solutions.
Shares of Vivus last traded at $12.55, up 9.3 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'
- Cummins (CMI) PT Lowered to $675 at Jefferies
Create E-mail Alert Related Categories
Analyst Comments, FDA, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
